The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

Halozyme Therapeutics (NASDAQ:HALO) announced on Wednesday that the European Commission has approved an injectable combo ...

Veteran oncology executive brings global development and regulatory expertise to support TCB's life sciences strategy HOUSTON, TX, UNITED STAT ...

Following hot on the heels of Monday’s European Commission EC approval of an indication extension for Johnson & Johnson’s ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has received approval from the European Commission (EC) ...

The commission approved the new formulation in first- and second-line NSCLC settings, in which intravenous Rybrevant is already available.

Halozyme (HALO) says the European Commission OK'd an injectable version of J&J's (JNJ) cancer drug, Rybrevant for certain ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved an extension of marketing ...

Halozyme Therapeutics (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson (JNJ) company, has received European ...

Tammy Selleck, Senior Product Specialist at Qualifacts, will lead the session. Ms. Selleck brings a unique perspective, ...

Daiichi Sankyo-partnered anti-HER2 drug Enhertu (trastuzumab deruxtecan) has been cleared by the European Commission for use ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Biotechnology industry for Wednesday, April 02, 2025. Let’s ...